$HPTX Headlines 2013 Biotech Watchlist Update: Companies

New Post Public Reply Private Reply Replies (0) Message Board

Dec 14, 2013 at 10:34 AM

$HPTX Headlines

2013 Biotech Watchlist Update: Companies Climb And Crumble On Catalysts 10:48 a.m. Nov. 1, 2013 - Seeking Alpha
Hyperion Therapeutics Grants Rights to Sobi to Distribute RAVICTI in Middle East 4:06 a.m. Oct. 1, 2013 - benzinga.com
Hyperion Presents Data on Ravicti - Analyst Blog 12:30 p.m. Sept. 5, 2013 - Zacks.com
Hyperion's Loss Narrows Y/Y - Analyst Blog 12:07 p.m. Aug. 20, 2013 - Zacks.com
10-Q/A: HYPERION THERAPEUTICS INC 4:10 p.m. Aug. 15, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-Q: HYPERION THERAPEUTICS INC 4:24 p.m. Aug. 14, 2013 - Edgar Online - (EDG = 10Q, 10K)
Hyperion Therapeutics Announces Ashley Gould as Chief Legal Officer 2:14 p.m. July 17, 2013 - benzinga.com
Data from Hyperion's UCD Drugs - Analyst Blog 6:30 p.m. June 24, 2013 - Zacks.com
Hyperion Acquires Buphenyl Rights - Analyst Blog 4:35 p.m. June 10, 2013 - Zacks.com
Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential 9:18 p.m. May 3, 2013 - Seeking Alpha
5 Biotechnology Stocks That Greatly Outperformed The Market In Q1 3:12 a.m. April 15, 2013 - Seeking Alpha
Hyperion Therapeutics Closes Follow-On Offering, Underwriters' Exercised Option 2:07 p.m. March 13, 2013 - benzinga.com
10-K/A: HYPERION THERAPEUTICS INC 2:32 p.m. Feb. 26, 2013 - Edgar Online - (EDG = 10Q, 10K)
Best-Performing Russell 3000 Stocks Year To Date 6:38 p.m. Feb. 11, 2013 - Seeking Alpha
Biotech Movers: A Doubler for Opexa 2:30 a.m. Feb. 11, 2013 - InvestorPlace.com
4 Healthcare Stock Stories for Tuesday Wellness 7:20 p.m. Feb. 5, 2013 - Wall St. Cheat Sheet
Hyperion Confirms FDA Approval for RAVICITI 2:02 p.m. Feb. 1, 2013 - benzinga.com
Market Bets On Approval For Hyperion's Ravicti On FDA's 'Hint' 1:07 p.m. Jan. 24, 2013 - Seeking Alpha
FDA Will Not Meet PDUFA Date for Hyperion's Ravicti 7:59 a.m. Jan. 16, 2013 - benzinga.com
Hyperion's Drug Ravicti Likely To Receive FDA Approval 11:30 a.m. Jan. 9, 2013 - Seeking Alpha

Hyperion Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference 4:05 p.m. Nov. 26, 2013 - GlobeNewswire
Hyperion Therapeutics to Present at the Jefferies 2013 London Healthcare Conference 9:00 a.m. Nov. 15, 2013 - GlobeNewswire
Hyperion Therapeutics Announces Third Quarter 2013 Financial Results 4:06 p.m. Nov. 12, 2013 - GlobeNewswire
Hyperion Therapeutics Announces Third Quarter 2013 Financial Results Teleconference and Webcast 9:00 a.m. Nov. 6, 2013 - GlobeNewswire
Hyperion Therapeutics Announces Initiation of THRIVE Study, a Long-Term Registry of Patients With Urea Cycle Disorders 8:00 a.m. Oct. 31, 2013 - GlobeNewswire
Sobi Gains Rights to Distribute RAVICTI(R) on a Named Patient Use Basis in Middle East From Hyperion Therapeutics, Inc. 6:00 a.m. Oct. 1, 2013 - GlobeNewswire
Sobi gains rights to distribute RAVICTI(R) on a named patient use basis in Middle East from Hyperion Therapeutics, Inc. 1:07 a.m. Oct. 1, 2013 - GlobeNewswire
Sobi gains rights to distribute RAVICTI® on a named patient use basis in Middle East from Hyperion Therapeutics, Inc. 1:02 a.m. Oct. 1, 2013 - Thomson Reuters ONE
Hyperion Therapeutics to Present at the Leerink Swann Rare Disease Day 8:01 a.m. Sept. 26, 2013 - GlobeNewswire
Hyperion Therapeutics to Present at the Annual Stifel 2013 Healthcare Conference 3:30 p.m. Sept. 5, 2013 - GlobeNewswire
Hyperion Therapeutics Announces Presentation of Long Term Data on Ammonia Control in Pediatric Patients Treated With RAVICTI(R) at the 12th International Congress of Inborn Errors of Metabolism and the Urea Cycle Disorder Satellite Symposium 7:00 a.m. Sept. 3, 2013 - GlobeNewswire
Hyperion Therapeutics Announces Second Quarter 2013 Financial Results 3:05 p.m. Aug. 14, 2013 - GlobeNewswire
Hyperion Therapeutics Announces Second Quarter 2013 Financial Results Teleconference and Webcast 3:30 p.m. Aug. 8, 2013 - GlobeNewswire
Hyperion Therapeutics Announces Larry J. Singer as Vice President, Manufacturing 8:15 a.m. Aug. 6, 2013 - GlobeNewswire
Hyperion Therapeutics Announces Three New Additions to Its Senior Leadership Team 3:05 p.m. July 17, 2013 - GlobeNewswire
R&D Milestones, Response on Published Reports, and Independent Clinical Programs Widen Growth Opportunities for Biotech Companies - Research Report on Verastem, Acorda, Hyperion, XOMA, and Lexicon 7:00 a.m. July 3, 2013 - PR Newswire
Hyperion Therapeutics to Present at the Eighth Annual JMP 2013 Global Healthcare Securities Conference 8:00 a.m. July 2, 2013 - GlobeNewswire
Wall Street Fundamentals Releases New In-Depth Stock Reports on CHTP, CLVS, HPTX and SGEN 7:32 a.m. June 28, 2013 - ACCESSWIRE
Hyperion Therapeutics Announces RAVICTI and BUPHENYL Pharmacokinetic Analyses Reported in The Journal of Clinical Pharmacology 7:12 a.m. June 18, 2013 - GlobeNewswire
Hyperion Therapeutics Acquires Worldwide Rights to BUPHENYL 8:01 a.m. June 3, 2013 - GlobeNewswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Antheia Secures $80M for Critical Medicine Onshoring

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Faith and Resilience in China: The Legacy of the Long March

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

AEVEX Faces 48-Hour Deadline for Investor Class Action

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

ASTS Faces a Legal Countdown – Investors Take Note

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Tomorrowland's Shanghai Return: An Electri-Lifesaver

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

UEG's New Advisory Board: Elevating Patient Voices

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Lundbeck's Board Leadership Transitions into New Era

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...